Response rates and secondary end points
| . | Tamibarotene + azacitidine . | Placebo + azacitidine . |
|---|---|---|
| CR, n (%) | 30 (23.1) | 12 (18.75) |
| Median duration of CR, (95% CI) | 15.7 (6.9 to NE) | NE |
| ORR, n (%) | 90 (71.43) | 45 (70.31) |
| Median duration of ORR, (95% CI), mo | 12 (7.9-22.1) | 19.4 (5.8 to NE) |
| Median time to initial response, (95% CI), mo | 1.0 | 1.1 |
| Achieved red cell TD at baseline n (%) | 35 (79.55) Of 44 TD at baseline | 16 (57.14) Of 28 TD at baseline |
| Patient who maintained red cell TI at baseline n (%) | 51 (89.47) Of 57 TI at baseline | 23 (82.14) Of 28 TI at baseline |
| . | Tamibarotene + azacitidine . | Placebo + azacitidine . |
|---|---|---|
| CR, n (%) | 30 (23.1) | 12 (18.75) |
| Median duration of CR, (95% CI) | 15.7 (6.9 to NE) | NE |
| ORR, n (%) | 90 (71.43) | 45 (70.31) |
| Median duration of ORR, (95% CI), mo | 12 (7.9-22.1) | 19.4 (5.8 to NE) |
| Median time to initial response, (95% CI), mo | 1.0 | 1.1 |
| Achieved red cell TD at baseline n (%) | 35 (79.55) Of 44 TD at baseline | 16 (57.14) Of 28 TD at baseline |
| Patient who maintained red cell TI at baseline n (%) | 51 (89.47) Of 57 TI at baseline | 23 (82.14) Of 28 TI at baseline |
ORR, overall response rate; TD, transfusion independence when dependent.